An acute myeloid leukemia in elderly patients: the special features of clinical course and treatment

<p><strong>Aim</strong><strong> </strong><strong>of</strong><strong> </strong><strong>research</strong><strong>. </strong>To analyze an effectiveness of treatment and survivability rate of patients with AMG of the elder age category (&gt; 60 years) among the Ukrainian patients. <strong></strong></p><p><strong>Materials</strong><strong> </strong><strong>and</strong><strong> </strong><strong>methods</strong><strong>. </strong>Patients were treated in the department of blood system diseases of SI “Institution of hematology and transfusiology of NAMS of Ukraine” during the period 2003-2015 years. There were retrospectively studied the data of 64 patients with AML older than 60 years that were compared with analogous parameters of 83 younger patients (18-60 years). <strong></strong></p><p><strong>Results</strong><strong> </strong><strong>of</strong><strong> </strong><strong>research</strong><strong>.</strong> In the group of elderly patients with AML the number of clinically-hematologic remissions was essentially lower than among the younger patients and was 14 % against 64,9 % (р &lt; 0,01). With the growth of age the number of the positive results of treatment significantly decreased. So in the age of 61-70 years old were obtained 23,5 % of remissions, in the age of 71-80 years the number of remissions was 5 %, and among patients older than 80 years the was no one remission. In the first year after diagnosis 48 (75 %) of 64 patients died and during the 2 year 60 patients died. The differences in survivability rate depending on age were statistically significant according to the results of log-rank test (р &lt; 0,005).</p><p><strong>Conclusions</strong><strong>. </strong>The number of obtained remissions correlated with the comorbid state of patient (r = 0,845, р &lt; 0,05). The cytostatic induced chemotherapy on the AML treatment standard «7+3» was carried out only in 25 % of cases, the age of patients who underwent it was 60-70 years. The general two-year survivability in elderly patients (&gt; 60 років) was only 6 %, as that in these cases we are talking about patients younger than 80 years old